Abstract
The aim of the present study was to investigate the effects of deoxycholic acid (DCA) on BGC-823 human gastric carcinoma cells and to explore the possible mechanisms underlying any such effects. Cell proliferation was detected using an MTT assay, cell morphology was observed by inverted microscopy, and cell cycle progression and the mitochondrial membrane potential were analyzed using flow cytometry. The expression of Bcl-2, Bax, p53, Cyclin D1 and CDK2 proteins was analyzed with western blotting. The results demonstrated that DCA significantly inhibited cell growth, arrested the cell cycle at the G1 phase, and induced apoptosis associated with the collapse of the mitochondrial membrane potential. The mitochondria-dependent pathway was activated via an increase in the Bax:Bcl-2 ratio, involving p53.
Introduction
Gastric carcinoma remains a leading cause of cancer-related mortality globally, particularly in China. While surgery, chemotherapy, and radiotherapy are standard treatments, the long-term outcomes for many patients remain poor. This study investigates the potential of deoxycholic acid (DCA), a common bile acid, as a novel antitumor agent against the BGC-823 human gastric carcinoma cell line.
Methods
Researchers treated BGC-823 cells with DCA concentrations ranging from 0.2 to 0.8 mM. Cell viability was quantified using the MTT assay at 24, 48, and 72 hours. Morphological hallmarks of apoptosis were visualized using Giemsa, Hoechst 33258, and Acridine Orange/Ethidium Bromide (AO/EB) staining. Flow cytometry was employed to analyze cell cycle distribution (via Propidium Iodide) and mitochondrial membrane potential ($\Delta\Psi m$) using Rhodamine 123 fluorescence. Finally, western blotting was used to measure the expression of key regulatory proteins: p53, Bax, Bcl-2, Cyclin D1, and CDK2.
Results
Growth Inhibition and Morphological Changes
DCA demonstrated a clear dose- and time-dependent inhibitory effect on BGC-823 cell proliferation. As shown in Figure 1, treatment with 0.8 mM DCA for 48 hours resulted in a staggering 95.02% inhibition rate. Microscopic analysis confirmed physical hallmarks of apoptosis, including cell shrinkage and nuclear fragmentation.
Cell Cycle Arrest and Mitochondrial Dysfunction
One of the most significant findings was that DCA induces G1 phase arrest, preventing cells from transitioning to the DNA synthesis (S) phase. In control groups, roughly 60.12% of cells were in the G1 phase; treatment with 0.3 mM DCA increased this to 88.35%. This arrest was molecularly supported by the downregulation of Cyclin D1 and CDK2.
Furthermore, DCA treatment led to a significant, dose-dependent collapse of the mitochondrial membrane potential, a critical step in the intrinsic apoptotic pathway (Figure 2).
Molecular Signaling
Western blot analysis revealed that DCA leverages the cell's natural tumor suppressor, p53. Upregulation of p53 was accompanied by an increased Bax:Bcl-2 ratio, shifting the cellular balance toward programmed cell death.
Discussion and Limitations
This study demonstrates that DCA effectively inhibits gastric carcinoma cell growth by triggering p53-mediated G1 arrest and mitochondrial apoptosis. However, several limitations remain. These results are based on in vitro cell cultures; the complex environment of a living organism may alter DCA's efficacy. Additionally, the concentrations used (up to 0.8 mM) are relatively high, and future research must determine if such levels are clinically achievable and safe for human patients. Further investigation into the upstream sensing mechanisms that activate p53 in response to DCA is also warranted.
Summary updated